Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of Crohn's disease (CD) for at least 3 months prior to Baseline.
Crohn's disease activity index (CDAI) score 220 - 450 at Baseline.
Confirmed diagnosis of moderate to severe Crohn's Disease as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic score for CD (SES-CD).
Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies.
You may not be if
Current diagnosis of ulcerative colitis or indeterminate colitis.
Receipt of CD approved biologic agents prior to Baseline (as detailed in protocol), or any investigational biologic or other agent or procedure prior to Baseline (as detailed in protocol).
Prior exposure to p19 and/or p40 inhibitors (e.g., risankizumab and ustekinumab).
Currently know complications of CD (strictures, short bowel, etc).
Clareo Health | Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
